Immatics presented Phase 1 clinical trial data for its IMA401 TCR bispecific targeting MAGEA4/8, showing durable responses and good tolerability in heavily pretreated solid tumor patients, including melanoma and head and neck cancer. The data, also published in Nature Medicine, support combining IMA401 with IMA402 (targeting PRAME) to enhance treatment for squamous cell non-small cell lung cancer (sqNSCLC), where over 90% of patients express one or both targets. Enrollment for the combination trial is underway with initial results expected in 2027, marking a significant step in developing off-the-shelf immunotherapies for solid tumors.
Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma patients, showing a 6-month overall survival rate of 87% and a disease control rate of 52%. The 160 mcg dose demonstrated better clinical outcomes and...
Apple's stock surged 15% in May, driven by optimism around its future in AI, particularly the potential of 'agentic smartphones.' Bank of America raised Apple's price target to $380, highlighting this AI opportunity as a key growth driver. Meanwhile,...
Victoria Hanrahan, a senior executive at Nokia, acquired a total of 44,682 Nokia shares on May 26 and May 28, 2026. The shares were purchased on the New York Stock Exchange at average prices of $16.02 and $15.60 respectively, with a combined average ...
Victoria Hanrahan, a senior manager at Nokia Corporation, purchased a total of 44,682 shares on May 26 and May 28, 2026. The shares were acquired on the New York Stock Exchange at an average price of $15.81 per share. This transaction signals confide...
Microsoft is poised for significant growth through its AI partnerships and cloud expansion, particularly its collaboration with Anthropic, which could generate up to $43 billion in annual revenue by 2030. The company is accelerating AI data center de...
